Press releases

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

Physicians will have continued access to the Eluvia™ Drug-Eluting Vascular Stent (DES) System to treat their patients with peripheral artery disease (PAD).

Boston Scientific will participate in an upcoming investor conference in August 2019. A live webcast and replay will be available.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.